SEC Comment Letter 0000000000-24-009233 to Annexon, Inc. (ANNX) (CIK 0001528115) (ANNX)
Annexon, Inc. (ANNX) (CIK 0001528115)
Date: Aug. 13, 2024 · CIK: 0001528115 · Accession: 0000000000-24-009233
AI Filing Summary & Sentiment
File numbers found in text: 333-281493
Letter
August 13, 2024 Douglas Love President and Chief Executive Officer Annexon, Inc. 1400 Sierra Point Parkway Bldg C, Suite 200 Brisbane, CA 94005 Re:Annexon, Inc. Registration Statement on Form S-3 Filed August 12, 2024 File No. 333-281493 Dear Douglas Love: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Anitha Anne
Show Raw Text
August 13, 2024
Douglas Love
President and Chief Executive Officer
Annexon, Inc.
1400 Sierra Point Parkway
Bldg C, Suite 200
Brisbane, CA 94005
Re:Annexon, Inc.
Registration Statement on Form S-3
Filed August 12, 2024
File No. 333-281493
Dear Douglas Love:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Anitha Anne